Precision medicine in recurrent glioblastoma: A feasibility trial conducted by the Ivy Foundation Early Phase Clinical Trials Consortium.

Abstract

2031Background: Pts with recurrent glioblastoma have median survival between 4 to 8 months. Precision-based therapies have not been used in this patient population. The goal of this trial was to determine the feasibility to make individualized treatment recommendations within at least 35 days of tumor tissue collection, using whole exome and RNA sequencing based upon those alterations. A sample size of at least 15 patients with sufficient tumor RNA and DNA was used to determine feasibility. Pts. had the option of accepting the recommendation or being treated using other treatment strategies. Adult patients with recurrent glioblastoma who were undergoing tumor resection at the time of relapse as part of their standard of care management were eligible. Methods: Tumor tissue was removed from both enhancing and non-enhancing regions of tumor and characterized by whole exome and RNA sequencing. Molecular profiles were done at Translational Genomics Research Institute (TGen), in a CLIA lab, matching genomic a...